Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials.

The Radiological Physics Center (RPC) has functioned continuously for 38 years to assure the National Cancer Institute and the cooperative groups that institutions participating in multi-institutional trials can be expected to deliver radiation treatments that are clinically comparable to those delivered by other institutions in the cooperative groups. To accomplish this, the RPC monitors the machine output, the dosimetry data used by the institutions, the calculation algorithms used for treatment planning, and the institutions' quality control procedures. The methods of monitoring include on-site dosimetry review by an RPC physicist and a variety of remote audit tools. The introduction of advanced technology clinical trials has prompted several study groups to require participating institutions and personnel to become credentialed, to ensure their familiarity and capability with techniques such as three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, stereotactic body radiotherapy, and brachytherapy. The RPC conducts a variety of credentialing activities, beginning with questionnaires to evaluate an institution's understanding of the protocol and their capabilities. Treatment-planning benchmarks are used to allow the institution to demonstrate their planning ability and to facilitate a review of the accuracy of treatment-planning systems under relevant conditions. The RPC also provides mailable anthropomorphic phantoms to verify tumor dose delivery for special treatment techniques. While conducting these reviews, the RPC has amassed a large amount of data describing the dosimetry at participating institutions. Representative data from the monitoring programs are discussed, and examples are presented of specific instances in which the RPC contributed to the discovery and resolution of dosimetry errors.

[1]  R. M. Wilenzick,et al.  Dose specification and quality assurance of radiation therapy oncology group protocol 95-17; a cooperative group study of iridium-192 breast implants as sole therapy. , 2007, International journal of radiation oncology, biology, physics.

[2]  Fran Laurie,et al.  The Impact of Central Quality Assurance Review Prior to Radiation Therapy on Protocol Compliance: POG 9426, a Trial in Pediatric Hodgkin’s Disease. , 2005 .

[3]  Avraham Eisbruch,et al.  Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. , 2005, International journal of radiation oncology, biology, physics.

[4]  Hak Choy,et al.  Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer , 2006, Acta oncologica.

[5]  G. Ibbott,et al.  Intensity-modulated radiation therapy for gynecologic cancers: pitfalls, hazards, and cautions to be considered. , 2006, Seminars in radiation oncology.

[6]  David S Followill,et al.  Design, development, and implementation of the radiological physics center's pelvis and thorax anthropomorphic quality assurance phantoms. , 2007, Medical physics.

[7]  Geoffrey S Ibbott,et al.  Credentialing of institutions for IMRT in clinical trials. , 2004, International journal of radiation oncology, biology, physics.

[8]  G. Ibbott,et al.  Dosimetric considerations for validation of a sequential IMRT process with a commercial treatment planning system. , 2002, Physics in medicine and biology.

[9]  James A. Purdy,et al.  Quality Assurance for Clinical Trials: A Primer for Physicists , 2004 .

[10]  David S Followill,et al.  Independent Evaluations of IMRT through the Use of an Anthropomorphic Phantom , 2006, Technology in cancer research & treatment.

[11]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .

[12]  Ravinder Nath,et al.  Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy. , 2005, Medical physics.